EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis

Matteo Franchi iD, Joel Gunnarsson iD, Emilio Gonzales-Parra, Anibal Ferreira, Oskar Ström, Giovanni Corrao iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad289 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Matteo Franchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics and Quantitative Methods, Bicocca University Milan, 20126 Milan, Italy. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vifor Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD) affecting mineral and bone metabolism and characterized by excessive parathyroid hormone (PTH) production and parathyroid hyperplasia.

Objective

The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paricalcitol (PCT) by assessing their effect on the biomarkers PTH, calcium, and phosphate in patients with non-dialysis CKD (ND-CKD).

Methods

A systematic literature research was performed in PubMed to identify randomized control trials (RCTs). Quality assessment was done with the GRADE method. The effects of ERC vs PCT were compared using random effects in a frequentist setting.

Results

Nine RCTs comprising 1426 patients were included in the analyses. The analyses were performed on 2 overlapping networks, due to nonreporting of outcomes in some of the included studies. No head-to-head trials were identified. No statistically significant differences in PTH reduction were found between PCT and ERC. Treatment with PCT showed statistically significant increases in calcium compared with ERC (0.2 mg/dL increase; 95% CI, −0.37 to −0.05 mg/dL). No differences in effects on phosphate were observed.

Conclusion

This network meta-analysis showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well-tolerated treatment option for the management of SHPT in patients with ND-CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, SecondaryRenal Insufficiency, ChronicHumansCalcifediolCalciumErgocalciferolsParathyroid HormonePhosphatesRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

bone/mineral metabolismhypercalcemiahyperparathyroidismmetabolic bone diseasevitamin D

Substanzen

CalcifediolCalciumErgocalciferolsParathyroid HormoneparicalcitolPhosphates

Autor:innen und Institutionen

  • Department of Statistics and Quantitative Methods, Bicocca University Milan, 20126 Milan, Italy.
  • Quantify Research, 112 21 Stockholm, Sweden.
  • Nephrology and Hypertension Clinic, Fundación Jiménez Díaz, 28040 Madrid, Spain.
  • NOVA Medical School, Faculty of Medical Sciences, Nova University of Lisbon, 1169-056 Lisbon, Portugal.
  • Department of Medicine, Huddinge, Karolinska Institutet, 141 57 Stockholm, Sweden.

ORCID-Profile: Matteo Franchi, Joel Gunnarsson, Giovanni Corrao

Förderung

  • Vifor Pharma

Zitieren

APA

Franchi, M., Gunnarsson, J., Gonzales-Parra, E., Ferreira, A., Ström, O., & Corrao, G. (2023). Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad289

Vancouver

Franchi M, Gunnarsson J, Gonzales-Parra E, Ferreira A, Ström O, Corrao G. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad289

BibTeX
@article{Franchi2023,
  author = {Franchi, Matteo and Gunnarsson, Joel and Gonzales-Parra, Emilio and Ferreira, Anibal and Ström, Oskar and Corrao, Giovanni},
  title = {Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad289}
}
Kostenlos starten →